2021
A Double-Blind, Randomized, Placebo-Controlled Trial of Soluble Epoxide Hydrolase Inhibition in Patients with Aneurysmal Subarachnoid Hemorrhage
Martini RP, Siler D, Cetas J, Alkayed NJ, Allen E, Treggiari MM. A Double-Blind, Randomized, Placebo-Controlled Trial of Soluble Epoxide Hydrolase Inhibition in Patients with Aneurysmal Subarachnoid Hemorrhage. Neurocritical Care 2021, 36: 905-915. PMID: 34873674, DOI: 10.1007/s12028-021-01398-8.Peer-Reviewed Original ResearchConceptsSoluble epoxide hydrolaseAneurysmal subarachnoid hemorrhageSubarachnoid hemorrhageDHET ratiosEnd pointDay 7Day 10Primary study end pointSoluble epoxide hydrolase inhibitionCSF inflammatory cytokinesEET/DHET ratiosIncidence of DCIPrevention of DCITertiary end pointSecondary end pointsStudy end pointCerebral blood flowLength of stayEndothelial injury biomarkersEpoxide hydrolase inhibitionNeurovascular inflammationResultsTen patientsStudy drugAdverse eventsCytokine levels
2011
Open-Label Randomized Trial of the Safety and Efficacy of a Single Dose Conivaptan to Raise Serum Sodium in Patients with Traumatic Brain Injury
Galton C, Deem S, Yanez ND, Souter M, Chesnut R, Dagal A, Treggiari M. Open-Label Randomized Trial of the Safety and Efficacy of a Single Dose Conivaptan to Raise Serum Sodium in Patients with Traumatic Brain Injury. Neurocritical Care 2011, 14: 354-360. PMID: 21409494, DOI: 10.1007/s12028-011-9525-8.Peer-Reviewed Original ResearchConceptsTraumatic brain injurySevere traumatic brain injuryUsual care groupIntracranial pressureSerum sodiumAdverse eventsUrine outputCare groupSodium loadBrain injuryDrug-related serious adverse eventsEffects of conivaptanLabel Randomized TrialNon-hyponatremic patientsSerum sodium increaseSerious adverse eventsTreatment of hyponatremiaSodium increasesMethodsOpen-labelNormonatremic patientsPrimary endpointResultsTen patientsSecondary endpointsUsual careMean sodium